VAISHALI

Vaishali Pharma Share Price

₹12.65 +0.01 (0.08%)

09 Jul, 2025 14:23

SIP TrendupStart SIP in VAISHALI

Start SIP

Performance

  • Low
  • ₹13
  • High
  • ₹13
  • 52 Week Low
  • ₹10
  • 52 Week High
  • ₹25
  • Open Price₹13
  • Previous Close₹13
  • Volume479,440

Investment Returns

  • Over 1 Month -1.33%
  • Over 3 Month + 1.28%
  • Over 6 Month -23.8%
  • Over 1 Year -21.38%
SIP Lightning

Smart Investing Starts Here Start SIP with Vaishali Pharma for Steady Growth!

Invest Now

Vaishali Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 201.9
  • PEG Ratio
  • 14.7
  • Market Cap Cr
  • 165
  • P/B Ratio
  • 2.4
  • Average True Range
  • 0.63
  • EPS
  • 0.08
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.26
  • RSI
  • 58.16
  • MFI
  • 36.68

Vaishali Pharma Financials

Vaishali Pharma Technicals

EMA & SMA

Current Price
₹12.65
+ 0.01 (0.08%)
pointer
  • stock-down_img
  • Bearish Moving Average 5
  • stock-up_img
  • Bullish Moving Average 11
  • 20 Day
  • ₹12.07
  • 50 Day
  • ₹12.45
  • 100 Day
  • ₹13.19
  • 200 Day
  • ₹14.28

Resistance and Support

12.44 Pivot Speed
  • R3 13.83
  • R2 13.30
  • R1 12.97
  • S1 12.11
  • S2 11.58
  • S3 11.25

What's your outlook on Vaishali Pharma?

You can only vote once!

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Vaishali Pharma has an operating revenue of Rs. 99.03 Cr. on a trailing 12-month basis. An annual revenue growth of 16% is outstanding, Pre-tax margin of 1% needs improvement, ROE of 1% is fair but needs improvement. The company has a reasonable debt to equity of 6%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 4 which is a POOR score indicating inconsistency in earnings, a RS Rating of 20 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 72 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of E is the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Vaishali Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-28 Audited Results & Others To consider other business matters split from Rs. 10/- to Rs. 2/-.
2025-02-06 Quarterly Results & Others To consider other business matters split from Rs. 10/- to Rs. 2/-.
2025-01-28 Others To consider other business matters split from Rs. 10/- to Rs. 2/-.
2024-11-14 Quarterly Results
2024-10-10 Others To consider other business matters split from Rs. 10/- to Rs. 2/-.
Date Purpose Remarks
2024-10-15 Split Rs.0.00 split from Rs. 10/- to Rs. 2/-.
Date Purpose Remarks
2024-10-15 Bonus Rs.0.00 issue in the ratio of 1:1 of Rs. 2/-

Vaishali Pharma F&O

Vaishali Pharma Shareholding Pattern

26.32%
65.24%
8.44%

About Vaishali Pharma

  • NSE Symbol
  • VAISHALI
  • BSE Symbol
  • Chairman & Managing Director
  • Mr. Atul Arvind Vasani
  • ISIN
  • INE972X01022

Similar Stocks to Vaishali Pharma

Vaishali Pharma FAQs

Vaishali Pharma share price is ₹12 As on 09 July, 2025 | 14:09

The Market Cap of Vaishali Pharma is ₹165 Cr As on 09 July, 2025 | 14:09

The P/E ratio of Vaishali Pharma is 201.9 As on 09 July, 2025 | 14:09

The PB ratio of Vaishali Pharma is 2.4 As on 09 July, 2025 | 14:09

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23